drugset / Trial / NCT00974675

A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate Asthma

NCT00974675

Phase 1 Terminated 23 enrolled MedImmune LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The study includes participants with moderate asthma who were randomly assigned to receive the study medication (CAT-354) or placebo.

Timeline

Start
2006-09-29
Primary completion
2007-08-03
Completion
2007-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Tralokinumab Monoclonal antibody 1 mg/kg Intravenous
Subject Tralokinumab Monoclonal antibody 5 mg/kg Intravenous
Subject Tralokinumab Monoclonal antibody 10 mg/kg Intravenous

Indications

No indication recorded.